A5068631395- Liver Disease Diagnosis and Treatment
- Drug Transport and Resistance Mechanisms
- Liver Diseases and Immunity
- Pediatric Hepatobiliary Diseases and Treatments
- Liver Disease and Transplantation
- Liver physiology and pathology
- Gallbladder and Bile Duct Disorders
- Drug-Induced Hepatotoxicity and Protection
- Organ Transplantation Techniques and Outcomes
- Metabolism and Genetic Disorders
- Pancreatitis Pathology and Treatment
- Pharmacological Effects and Toxicity Studies
- Inflammatory Bowel Disease
- Gut microbiota and health
- Diet and metabolism studies
- Hepatitis C virus research
- Hepatitis B Virus Studies
- Helicobacter pylori-related gastroenterology studies
- Macrophage Migration Inhibitory Factor
- Skin and Cellular Biology Research
- Clinical Nutrition and Gastroenterology
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Trace Elements in Health
- Fibroblast Growth Factor Research
- Alcohol Consumption and Health Effects
Medical University of Graz
2016-2025
Graz University Hospital
2020-2023
Medical University of Vienna
2012-2019
Groupe d'Étude Thérapeutique des Affections Inflammatoires du Tube Digestif
2018
University of Graz
2000-2016
Ludwig-Maximilians-Universität München
2016
Krankenhaus Barmherzige Brüder
2016
Creative Research Enterprises (United States)
2016
University of Cologne
2015
Laboratory of Molecular Genetics
2010-2014
Primary sclerosing cholangitis (PSC) represents a devastating bile duct disease, currently lacking effective medical therapy. 24-norursodeoxycholic acid (norUDCA) is side chain-shortened C23 homologue of UDCA and has shown potent anti-cholestatic, anti-inflammatory anti-fibrotic properties in preclinical PSC mouse model. A randomized controlled trial, including 38 centers from 12 European countries, evaluated the safety efficacy three doses oral norUDCA (500mg/d, 1,000mg/d or 1,500mg/d)...
MAIN RECOMMENDATIONS 1 ESGE/EASL recommend that, as the primary diagnostic modality for PSC, magnetic resonance cholangiography (MRC) should be preferred over endoscopic retrograde cholangiopancreatography (ERCP). Moderate quality evidence, strong recommendation. 2 suggest that ERCP can considered if MRC plus liver biopsy is equivocal or contraindicated in patients with persisting clinical suspicion of PSC. The risks have to weighed against potential benefit regard surveillance and treatment...
Induction of hepatic phase I/II detoxification enzymes and alternative excretory pumps may limit hepatocellular accumulation toxic biliary compounds in cholestasis. Because the nuclear xenobiotic receptors constitutive androstane receptor (CAR) pregnane X (PXR) regulate involved transporters, we aimed to induce adaptive pathways with different CAR PXR agonists vivo. Mice were treated phenobarbital 1,4-bis-[2-(3,5-dichlorpyridyloxy)]benzene, as well atorvastatin pregnenolone-16α-carbonitrile....
Chronic cholangiopathies have limited therapeutic options and represent an important indication for liver transplantation. The nuclear farnesoid X receptor (FXR) the membrane G protein-coupled receptor, TGR5, regulate bile acid (BA) homeostasis inflammation. Therefore, we hypothesized that activation of FXR and/or TGR5 could ameliorate injury in Mdr2(-/-) (Abcb4(-/-)) mice, a model chronic cholangiopathy. Hepatic inflammation, fibrosis, as well secretion key genes BA were addressed mice fed...
The bile acid receptor farnesoid X (FXR) is a key regulator of hepatic defense mechanisms against acids. A comprehensive study addressing the role FXR in coordinated regulation adaptive including biosynthesis, metabolism, and alternative export together with their functional significance lacking. We therefore fed knockout (FXR −/− ) mice cholic (CA) ursodeoxycholic (UDCA). Bile synthesis hydroxylation were assessed by real-time RT-PCR for cytochrome P-450 (Cyp)7a1, Cyp3a11, Cyp2b10 mass...
Approximately 95% of bile acids (BAs) excreted into are reabsorbed in the gut and circulate back to liver for further biliary secretion. Therefore, pharmacological inhibition ileal apical sodium-dependent BA transporter (ASBT/SLC10A2) may protect against BA-mediated cholestatic duct injury.Eight week old Mdr2(-/-) (Abcb4(-/-)) mice (model injury sclerosing cholangitis) received either a diet supplemented with A4250 (0.01% w/w) - highly potent selective ASBT inhibitor or chow diet. Liver was...
Tubular epithelial injury represents an underestimated but important cause of renal dysfunction in patients with cholestasis and advanced liver disease, the underlying mechanisms are unclear. To address hypothesis that accumulation excessive alternative urinary elimination potentially toxic bile acids (BAs) may contribute to kidney cholestasis, we established a mouse model for detailed vivo time course as well treatment studies. Three-day common duct ligation (CBDL) induced tubular...